Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic.
Physiol Res. 2019 Dec 20;68(Suppl 3):S315-S323. doi: 10.33549/physiolres.934350.
Autism spectrum disorder (ASD) is a neurodevelopmental condition with increasing incidence. Recent evidences suggest glial cells involvement in autism pathophysiology. S100B is a calcium binding protein, mainly found in astrocytes and therefore used as a marker of their activity. In our study, children with autism had higher plasma concentrations of S100B compared to non-autistic controls. No association of S100B plasma levels with behavioral symptoms (ADI-R and ADOS-2 scales) was found. Plasma S100B concentration significantly correlated with urine serotonin, suggesting their interconnection. Correlation of plasma S100B levels with stool calprotectin concentrations was found, suggesting not only brain astrocytes, but also enteric glial cells may take part in autism pathogenesis. Based on our findings, S100B seems to have a potential to be used as a biomarker of human neurodevelopmental disorders, but more investigations are needed to clarify its exact role in pathomechanism of autism.
自闭症谱系障碍(ASD)是一种神经发育障碍,发病率不断上升。最近的证据表明,神经胶质细胞参与了自闭症的病理生理学过程。S100B 是一种钙结合蛋白,主要存在于星形胶质细胞中,因此被用作其活性的标志物。在我们的研究中,自闭症儿童的血浆 S100B 浓度明显高于非自闭症对照组。S100B 血浆水平与行为症状(ADI-R 和 ADOS-2 量表)之间没有相关性。血浆 S100B 浓度与尿 5-羟色胺显著相关,表明它们之间存在相互联系。还发现了血浆 S100B 水平与粪便钙卫蛋白浓度之间的相关性,这表明不仅大脑星形胶质细胞,而且肠神经胶质细胞可能参与了自闭症的发病机制。基于我们的发现,S100B 似乎有可能被用作人类神经发育障碍的生物标志物,但需要进一步研究来阐明其在自闭症发病机制中的确切作用。